David C. Myles - 10 Dec 2021 Form 4 Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Role
CHIEF DEVELOPMENT OFFICER
Signature
/s/ John B. Moriarty, Jr., Attorney-in-Fact
Issuer symbol
OLMA
Transactions as of
10 Dec 2021
Transactions value $
-$103,000
Form type
4
Filing time
14 Dec 2021, 15:03:49 UTC
Next filing
03 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OLMA Common Stock Sale -$103K -10K -1.69% $10.30 583K 10 Dec 2021 Direct F1, F2
holding OLMA Common Stock 12.8K 10 Dec 2021 See Footnote F3
holding OLMA Common Stock 155K 10 Dec 2021 See Footnote F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 T he weighted average sale price for the transaction reported was $10.30, and the range of prices was between $10.23 and $10.50. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F2 Includes 589 shares acquired under the issuer's Employee Stock Purchase Plan on May 14, 2021, and 491 shares acquired under the issuer's Employee Stock Purchase Plan on November 15, 2021.
F3 The shares are held by The Myles Family Revocable Inter Vivos Trust, of which the Reporting Person is trustee.
F4 The shares are held by Myles Properties Inc., of which the Reporting Person is President.